Tyra Biosciences, Inc. (TYRA)
$18.56-5.31%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.1B
- Beta
- 0.75
- P/E (TTM)
- -7.73
- Short % float
- 21.24%
- Days to cover
- 8.8
- SI change
- -4.7%
- 1W
- -8.30%
- 1M
- -25.97%
- vs SPY 1W
- -8.16%
- vs SPY 1M
- -28.47%
Industry peers
FMP comparable companies · ranked by market cap
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00-3.67%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.99-4.23%
- BCAXSELLBicara Therapeutics Inc. Common Stock$1.1BCRISISQ -9$17.50+0.06%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 11$18.39-5.34%
- CGEMSELLCullinan Therapeutics, Inc.$954MCRISISQ 1$15.53-5.69%
- KURASELLKura Oncology, Inc.$941MCRISISQ 12$10.60-5.48%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -6$16.73-2.25%
- VSTMBUYVerastem, Inc.$736MRECOVERYQ 4$8.38-9.70%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on TYRA?
- LOPJLB’s latest quantitative signal on Tyra Biosciences, Inc. (TYRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TYRA in?
- Tyra Biosciences, Inc. (TYRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Tyra Biosciences, Inc. (TYRA) do?
- Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is adva…